Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05011916
Other study ID # 2021KYPJ139
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date August 10, 2021
Est. completion date August 9, 2022

Study information

Verified date August 2021
Source Zhongshan Ophthalmic Center, Sun Yat-sen University
Contact Qian Wang, PhD
Phone 18843014719
Email 419059130@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

KDR2-2, as a tyrosine kinase inhibitor, has a strong inhibitory effect on VEGFR2 and a moderate inhibitory effect on PDGFR-β. It can be used for the treatment of corneal neovascularization. The main purpose of this study is to explore the efficacy and safety of KDR2-2 suspension eye drops in the treatment of corneal neovascularization. This study is a single-center, prospective, randomized controlled clinical study. A total of 60 patients with corneal neovascularization were enrolled in this study, and they were randomly divided into 4 groups, including the control group, the KDR2-2 low-concentration (4mg/ml) group, the medium-concentration (10mg/ml) group, and the high-concentration (20mg/ml) group, with 15 subjects in each group. The control group applied 0.1% fluorometholone eye drops, and the test groups applied KDR2-2 suspension eye drops with 0.1% fluorometholone eye drops. Patients applied KDR2-2 eye drops four times daily for 6 weeks and were followed up to 10 weeks. The follow-up time points were baseline, 1 week, 2 weeks, 4 weeks, 6 weeks after medication, and 4 weeks after drug withdrawal. Relevant ophthalmological examinations (including visual acuity, intraocular pressure, slit lamp microscopy, central corneal thickness measurement, corneal fluorescein staining assessment, corneal sensitivity measurement, corneal confocal microscope examination, and anterior segment and fundus photography) are performed at each time. And the ocular tolerability score and adverse events of each patient were recorded. By comparative analysis, the efficacy and safety of KDR2-2 eye drops in the treatment of corneal neovascularization were evaluated.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date August 9, 2022
Est. primary completion date August 9, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. voluntarily participate in the trial, sign the informed consent form, and follow up according to the time specified by the trial; 2. 18~75 years old, without gender limit; 3. Superficial or deep corneal progressive neovascularization induced by trauma, chemical burns, corneal transplantation and inflammation: the growth of corneal new vessels= 2 mm from the limbus within 1 week to 2 months. Exclusion Criteria: 1. Obvious corneal epithelial defects (>1mm), or a history of persistent corneal epithelial defects in the past 3 months (>1mm, =14 days); 2. Anti-VEGF drugs have been injected locally in the target eye within 3 months, or anti-VEGF drugs have been used systemically within 2 months; 3. Recent eye surgery (except for keratoplasty) within 3 months, or planned eye surgery during the trial period; 4. Systemic use of glucocorticoid drugs, or intraocular or periocular injection of glucocorticoid drugs within 1 month; 5. Contact lenses use within the past 2 weeks (except bandage lenses); 6. Stable corneal neovascularization: > 6 months; 7. History of coagulation abnormalities (such as end-stage liver disease), or current anticoagulant drugs other than aspirin (such as warfarin, heparin, enoxaparin or similar anticoagulants); 8. Uncontrolled clinical problems (such as tumors, HIV infection, hepatitis C virus infection, active hepatitis B or other serious chronic infections, serious mental, neurological, cardiovascular, urinary, respiratory and other system diseases, etc.); Uncontrolled hypertension: systolic blood pressure =150mmHg or diastolic blood pressure =90mmHg; uncontrolled diabetes: A1C>7%; 9. Unwillingness/inability to take effective contraceptive measures during the trial period; 10. Female subjects have a positive blood pregnancy test; 11. Participated in a drug clinical trial within 3 months; 12. The investigator believes that it is not suitable for inclusion.

Study Design


Intervention

Drug:
KDR2-2 suspension eye drops
All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.

Locations

Country Name City State
China Zhongshan Ophthalmic Center, Sun Yat-Sen University Guangzhou
China Zhongshan Opthalmic Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Zhongshan Ophthalmic Center, Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the changes of the size and extent of corneal neovascularization The ef?cacy of KDR2-2 eye drops treatment on corneal neovascularization was evaluated by comparing corneal anterior segment photographs acquired at baseline with photographs acquired on the follow-up visits. Size and extent of CNV was investigated by four primary metrics: (1) neovascular area ratio, the ration of the area of the neovascularization to the area of the cornea, (2) vessel length (VL), the total length of the vessels projected into the cornea, (3) vessel caliber, the mean diameter of the corneal vessels, and (4) Corneal neovascularization progression/stabilization/regression rate Baseline, 1 week, 2 weeks, 4 weeks and 6 weeks after medication, and 4 weeks after drug withdrawal
Secondary the changes of visual acuity The uncorrected visual acuity and best corrected visual acuity were assessed through ETDRs chart at baseline and all the follow-up visits. The alterations in visual acuity were evaluated in all patients. Baseline, 1 week, 2 weeks, 4 weeks and 6 weeks after medication, and 4 weeks after drug withdrawal
Secondary the changes of intraocular pressure The intraocular pressure of the patients was assessed by iCARE at baseline and all the follow-up visits. The alterations of intraocular pressure were evaluated. Baseline, 1 week, 2 weeks, 4 weeks and 6 weeks after medication, and 4 weeks after drug withdrawal
Secondary the changes of central corneal thickness The central corneal thickness was assessed by anterior segment OCT at baseline and all the follow-up visits. The alterations in central corneal thickness were evaluated. Baseline, 1 week, 2 weeks, 4 weeks and 6 weeks after medication, and 4 weeks after drug withdrawal
Secondary the changes of conjunctival hyperemia score The conjunctival hyperemia score was assessed by severity from 0 (no signs of conjunctival hyperemia) to 3 (serious conjunctival hyperemia) by the clinician at baseline and all the follow-up visits.The changes of conjunctival hyperemia score were evaluated. Baseline, 1 week, 2 weeks, 4 weeks and 6 weeks after medication, and 4 weeks after drug withdrawal
Secondary the changes of corneal fluorescein staining score The corneal fluorescein staining score was assessed by NEI grading system by the clinician at baseline and all the follow-up visits.The NEI grading system divides the cornea into 5 zones: central, superior, temporal, nasal, and inferior. For each zone, the amount of corneal ?uorescein staining is graded on a scale of 0 to 3: 0=normal or negative slit-lamp ?ndings; 1=milder superfacial stippling; 2=moderate or punctate staining, including superfacial abrasion of the cornea; and 3=severe abrasion or corneal erosion, deep corneal abrasion, or recurrent erosion. The alterations in corneal fluorescein staining score were evaluated. Baseline, 1 week, 2 weeks, 4 weeks and 6 weeks after medication, and 4 weeks after drug withdrawal
Secondary the changes of corneal sensation The corneal sensation was assessed through Cochet-Bonnet aesthesiometer by the clinician at baseline and 4 weeks after drug withdrawal. The corneal sensation was assessed at five points on the cornea, including the central, superior, temporal, nasal, and inferior points. Baseline and 4 weeks after drug withdrawal
Secondary the morphological changes of corneal subepithelial nerve In vivo confocal laser scanning microscopy was performed by the clinician at baseline and 4 weeks after drug withdrawal. The density and length of the corneal subepithelial nerve were analysed. Baseline and 4 weeks after drug withdrawal
Secondary the changes of ocular tolerability score Ocular tolerability score (including ocular tolerability, burning sensation, pain, itching and blurred vision) was assessed by severity from 0 (absent) to 3 (severe) by questionnaire. 1 week, 2 weeks, 4 weeks and 6 weeks after medication
See also
  Status Clinical Trial Phase
Completed NCT00555594 - Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization Phase 2/Phase 3
Completed NCT00004430 - Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization N/A
Completed NCT00769145 - Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery Phase 1
Completed NCT01257750 - Treatment of Corneal Neovascularization With Topical Pazopanib Phase 1/Phase 2
Recruiting NCT04787471 - Corneal Crosslinking for Treatment of Corneal Neovascularization Phase 2/Phase 3
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Active, not recruiting NCT00992849 - Bevacizumab for the Treatment of Corneal Neovascularization Phase 2
Withdrawn NCT00515684 - Corneal Thinning During Topical Bevacizumab Therapy N/A
Terminated NCT02797704 - Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Phase 1/Phase 2
Terminated NCT01868360 - Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea Phase 1
Withdrawn NCT02042027 - Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Phase 1
Recruiting NCT04215393 - An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization Phase 1
Completed NCT00797303 - The Effect of Bevacizumab on Corneal Neovascularization Phase 4
Recruiting NCT05659940 - Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
Completed NCT00559936 - Topical Avastin for Treatment of Corneal Neovascularization Phase 1
Completed NCT01072357 - Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Phase 1/Phase 2
Recruiting NCT04620109 - Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment Phase 1
Completed NCT00512876 - Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization N/A
Completed NCT01996826 - A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Phase 1/Phase 2
Terminated NCT00915590 - Topical IL-1-Ra for Treatment of Corneal Neovascularization Phase 1/Phase 2